Filing Flows › Comparisons › LAB vs FBIO
Standard Biotools vs Fortress Biotech: LAB and FBIO compared
Standard Biotools is the larger company: $19.4M of revenue in its latest quarter (Q3 2026) against $18.7M for Fortress Biotech (Q2 2026). Fortress Biotech is growing faster (+14% against -0.9% a year earlier). Fortress Biotech is more profitable, with an operating margin of -53.5% against -102.0%.
Where the money goes: LAB and FBIO
Standard Biotools (LAB) · Q3 2026
Standard Biotools, Q3 2026: revenue $19.4M (-0.9% year over year), operating margin -102.0%, net earnings $13.5M, operating cash flow −$6.2M. The chart follows the revenue to costs, profit and cash.
Fortress Biotech (FBIO) · Q2 2026
Fortress Biotech, Q2 2026: revenue $18.7M (+14% year over year), operating margin -53.5%, net earnings $602K, operating cash flow −$59.3M. The chart follows the revenue to costs, profit and cash.
| Standard Biotools (LAB) | Fortress Biotech (FBIO) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $19.4M | $18.7M |
| Revenue growth, Y/Y | -0.9% | +14% |
| Operating margin | -102.0% | -53.5% |
| Net earnings | $13.5M | $602K |
| Net margin | 69.6% | 3.2% |
| Operating cash flow | −$6.2M | −$59.3M |
Where the revenue comes from
Standard Biotools
- Product: $14.3M (74%)
- Services and Other Revenue: $5.1M (26%)
Fortress Biotech
- Journey: $18.5M (99%)
- Fortress: $208K (1%)
Questions
Which is bigger, Standard Biotools or Fortress Biotech?
Standard Biotools is the larger company: $19.4M of revenue in its latest quarter (Q3 2026) against $18.7M for Fortress Biotech (Q2 2026).
Is Standard Biotools or Fortress Biotech growing faster?
Fortress Biotech is growing faster (+14% against -0.9% a year earlier).
Which is more profitable, Standard Biotools or Fortress Biotech?
Fortress Biotech is more profitable, with an operating margin of -53.5% against -102.0%.
More: Standard Biotools earnings · how Standard Biotools makes money · Fortress Biotech earnings · how Fortress Biotech makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 3, 2026; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.